Equities analysts predict that XOMA Co. (NASDAQ:XOMA) will post ($0.52) earnings per share for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for XOMA’s earnings, with the highest EPS estimate coming in at ($0.15) and the lowest estimate coming in at ($0.99). XOMA posted earnings per share of ($2.30) in the same quarter last year, which suggests a positive year over year growth rate of 77.4%. The company is scheduled to issue its next quarterly earnings report on Tuesday, May 8th.
On average, analysts expect that XOMA will report full-year earnings of ($1.24) per share for the current fiscal year, with EPS estimates ranging from ($1.80) to ($0.85). For the next year, analysts expect that the company will post earnings of ($1.09) per share, with EPS estimates ranging from ($1.32) to ($0.65). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that cover XOMA.
XOMA (NASDAQ:XOMA) last posted its quarterly earnings results on Wednesday, March 7th. The biotechnology company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.19. XOMA had a net margin of 27.49% and a negative return on equity of 130.44%. The business had revenue of $5.36 million for the quarter, compared to analysts’ expectations of $4.12 million.
Several equities analysts have recently commented on the stock. HC Wainwright restated a “buy” rating and set a $49.00 price target on shares of XOMA in a report on Thursday, January 18th. ValuEngine upgraded shares of XOMA from a “sell” rating to a “hold” rating in a report on Friday, March 9th. Wedbush restated a “buy” rating and set a $33.00 price target on shares of XOMA in a report on Tuesday, December 19th. Zacks Investment Research cut shares of XOMA from a “hold” rating to a “sell” rating in a report on Friday, March 9th. Finally, TheStreet upgraded shares of XOMA from an “e+” rating to a “c-” rating in a report on Wednesday, November 29th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $38.33.
XOMA (NASDAQ:XOMA) traded down $1.00 during trading on Tuesday, hitting $21.35. 125,915 shares of the stock traded hands, compared to its average volume of 195,358. The company has a debt-to-equity ratio of 2.52, a quick ratio of 5.96 and a current ratio of 5.96. XOMA has a fifty-two week low of $5.35 and a fifty-two week high of $37.25. The stock has a market cap of $187.49, a PE ratio of -40.28 and a beta of 3.03.
A number of large investors have recently modified their holdings of XOMA. Millennium Management LLC boosted its holdings in XOMA by 1,404.7% in the fourth quarter. Millennium Management LLC now owns 196,759 shares of the biotechnology company’s stock worth $7,005,000 after purchasing an additional 183,683 shares in the last quarter. Bogle Investment Management L P DE bought a new stake in XOMA in the fourth quarter worth $3,657,000. Two Sigma Investments LP boosted its holdings in XOMA by 717.5% in the fourth quarter. Two Sigma Investments LP now owns 88,692 shares of the biotechnology company’s stock worth $3,157,000 after purchasing an additional 77,843 shares in the last quarter. EAM Investors LLC bought a new stake in XOMA in the third quarter worth $835,000. Finally, AXA bought a new stake in XOMA in the fourth quarter worth $1,211,000. Hedge funds and other institutional investors own 38.90% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “XOMA Co. (XOMA) Expected to Announce Earnings of -$0.52 Per Share” was first reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at https://www.thelincolnianonline.com/2018/03/20/xoma-co-xoma-expected-to-announce-earnings-of-0-52-per-share.html.
XOMA Company Profile
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.